每年專案
個人檔案
學歷
- 2002-2007 Postdoctoral training in Hematology and Oncology, Mount Sinai School of Medicine, New York, USA
- 1997.09-2002.05 美國紐約市立大學Biology博士
- 1994.09-1997.07 美國紐約市立大學Biology碩士
- 1984.09-1988.06 國立中興大學植物病理學系學士
經歷
- 2024.08- 臺北醫學大學醫學科學研究所教授
- 2018.02- 臺北醫學大學國際醫學研究碩士學位學程副教授
- 2018.02- 臺北醫學大學細胞治療與再生醫學國際博士學位副教授
- 2016.11-2017.10 臺北醫學大學國際醫學研究碩士學位學程副教授
- 2013.02-2024.07 臺北醫學大學醫學科學研究所副教授
- 2009.08-2013.07 臺北醫學大學醫學科學研究所助理教授
- 2009.02-2009.07 中山醫學大學微生物免疫研究所助理教授
- 2007.10-2008.10 Research Associate, Hematology and Oncology/Medicine, Mount Sinai School of Medicine, New York, USA
- 1994-2008 Postdoctoral Fellow, Hematology and Oncology/Medicine, Mount Sinai School of Medicine, New York, USA
- 1994-2001 Adjunct Lecturer, Biology, Queens College, City University of New York
獎項
- 2007 Travel Award, ASH 50th Annual Meeting, San Diego, CA
研究興趣
- Leukocyte trafficking, Cancer biology, Wound healing, Traumatic brain injury
與 UN SDG 相關的專業知識
聯合國會員國於 2015 年同意 17 項全球永續發展目標 (SDG)，以終結貧困、保護地球並確保全體的興盛繁榮。此人的作品有助於以下永續發展目標：
-
SDG 3 良好的健康和福祉 -
SDG 9 產業、創新與基礎設施
指紋
查看啟用 Jungshan Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
專案
- 16 已完成
-
乳癌細胞尼古丁受體表現與新穎抗體奈米藥物之臨床前試驗評估-α9尼古丁受體於小鼠模式探討致癌機制與奈米藥物之臨床前試驗評估(3/3)
Chang, J. (PI)
8/1/19 → 7/31/20
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
乳癌細胞尼古丁受體表現與新穎抗體奈米藥物之臨床前試驗評估-α9尼古丁受體於小鼠模式探討致癌機制與奈米藥物之臨床前試驗評估(2/3)
Chang, J. (PI)
8/1/18 → 8/1/19
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
乳癌細胞尼古丁受體表現與新穎抗體奈米藥物之臨床前試驗評估-α9尼古丁受體於小鼠模式探討致癌機制與奈米藥物之臨床前試驗評估(1/3)
Chang, J. (PI)
8/1/17 → 7/31/18
研究計畫: A - 政府部門 › b - 國家科學及技術委員會
-
-
-
An innovative hierarchical porous oxide surface with enhanced surface area for promoting early-stage bone regeneration potential
Shen, C. L., Hung, K. S., Shen, H. T., Ou, Y. S. J., Chang, J., Tsai, C. H., Saito, T., Pao, Y. R., Ou, K. L., Tsai, C. M. & Wei, X., 12月 2026, 於: Journal of Materials Science: Materials in Medicine. 37, 1, 49.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Correction: Blocking heme oxygenase-1 by zinc protoporphyrin reduces tumor hypoxia-mediated VEGF release and inhibits tumor angiogenesis as a potential therapeutic agent against colorectal cancer (Journal of Biomedical Science, (2016), 23, 1, (18), 10.1186/s12929-016-0219-6)
Cheng, C. C., Guan, S. S., Yang, H. J., Chang, C. C., Luo, T. Y., Chang, J. & Ho, A. S., 12月 2026, 於: Journal of Biomedical Science. 33, 1, 78.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
Apoptotic Effect of Simpor Leaf Extract (Dillenia suffruticosa) from Belitung on Colorectal Cancer Cells WiDr
Rahayu, S., Rinendyaputri, R., Nikmah, U. A., Supriyatin, Irnidayanti, Y., Priambodo, R., Nazlihatunnisa, Rusmalina, D. L., Syahira, R. H. & Chang, J., 12月 2024, 於: Walailak Journal of Science and Technology. 21, 12, 8316.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取 -
Characterization of chicken-derived antibody against Alpha-Enolase of Streptococcus pneumoniae
Lee, C. H., Wu, C. J., Yang, Y. Y., Wang, W. C., Leu, S. J., Wu, C. T., Kao, P. S., Liu, K. J., Tsai, B. Y., Chiang, Y. W., Mao, Y. C., Benedict Dlamini, N. & Chang, J., 2月 15 2024, 於: International Immunopharmacology. 128, 111476.研究成果: 雜誌貢獻 › 文章 › 同行評審
7 連結會在新分頁中打開 引文 斯高帕斯（Scopus） -
Engineering H2O2 Self-Supplying Platform for Xdynamic Therapies via Ru-Cu Peroxide Nanocarrier: Tumor Microenvironment-Mediated Synergistic Therapy
Dirersa, W. B., Kan, T. C., Chang, J., Getachew, G., Ochirbat, S., Kizhepat, S., Wibrianto, A., Rasal, A., Chen, H. A., Ghule, A. V., Chou, T. H. & Chang, J. Y., 5月 15 2024, 於: ACS Applied Materials and Interfaces. 16, 19, p. 24172-24190 19 p.研究成果: 雜誌貢獻 › 文章 › 同行評審
開啟存取54 連結會在新分頁中打開 引文 斯高帕斯（Scopus）
資料集
-
MOESM10 of STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
Chiang, Y.-W. (Creator), Lim, K.-H. (Contributor), Sie, Z.-L. (Creator), Chang, Y.-F. (Creator), Chang, J. (Creator), Ho, A.-S. (Contributor) & Cheng, C.-C. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.9993536.v1, https://doi.org/10.6084%2Fm9.figshare.9993536.v1
資料集: Dataset
-
MOESM8 of STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
Lim, K.-H. (Contributor), Chiang, Y.-W. (Creator), Sie, Z.-L. (Creator), Chang, J. (Creator), Chang, Y.-F. (Creator), Ho, A.-S. (Contributor) & Cheng, C.-C. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.9993593.v1, https://doi.org/10.6084%2Fm9.figshare.9993593.v1
資料集: Dataset
-
MOESM4 of STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
Cheng, C.-C. (Contributor), Sie, Z.-L. (Creator), Lim, K.-H. (Contributor), Chang, J. (Creator), Chiang, Y.-W. (Creator), Chang, Y.-F. (Creator) & Ho, A.-S. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.9993569.v1, https://doi.org/10.6084%2Fm9.figshare.9993569.v1
資料集: Dataset
-
STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
Chang, Y.-F. (Creator), Lim, K.-H. (Contributor), Chiang, Y.-W. (Creator), Sie, Z.-L. (Creator), Chang, J. (Creator), Ho, A.-S. (Contributor) & Cheng, C.-C. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.c.4701632.v1, https://doi.org/10.6084%2Fm9.figshare.c.4701632.v1
資料集: Dataset
-
MOESM9 of STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers
Lim, K.-H. (Contributor), Ho, A.-S. (Contributor), Sie, Z.-L. (Creator), Chiang, Y.-W. (Creator), Cheng, C.-C. (Contributor), Chang, J. (Creator) & Chang, Y.-F. (Creator), Figshare, 2019
DOI: 10.6084/m9.figshare.9993596.v1, https://doi.org/10.6084%2Fm9.figshare.9993596.v1
資料集: Dataset